Anabuse: Clinically Proven Alcohol Deterrent Therapy
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.11 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $82.23 $66.18 (20%) | 🛒 Add to cart |
| 90 | $1.01 | $123.34 $91.25 (26%) | 🛒 Add to cart |
| 120 | $0.98 | $164.46 $117.32 (29%) | 🛒 Add to cart |
| 180 | $0.94 | $246.68 $168.47 (32%) | 🛒 Add to cart |
| 270 | $0.90 | $370.02 $243.67 (34%) | 🛒 Add to cart |
| 360 | $0.88
Best per pill | $493.37 $317.88 (36%) | 🛒 Add to cart |
Synonyms | |||
Anabuse (disulfiram) is a prescription medication designed to support the treatment of chronic alcoholism by creating an aversive physiological response to alcohol consumption. It functions as a deterrent therapy, discouraging alcohol intake through the induction of unpleasant effects when ethanol is ingested. Administered under medical supervision, Anabuse is a cornerstone in comprehensive addiction management protocols, aiding motivated individuals in maintaining sobriety. Its efficacy is well-documented in clinical settings when used as part of a broader therapeutic strategy that includes counseling and behavioral support.
Features
- Active ingredient: Disulfiram 250 mg or 500 mg tablets
- Mechanism: Inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation upon alcohol consumption
- Administration: Oral tablet, once daily
- Prescription status: Schedule IV controlled substance
- Packaging: Blister packs with child-resistant containers
- Manufacturer compliance: Current Good Manufacturing Practice (cGMP) certified
- Shelf life: 24 months from date of manufacture
- Bioavailability: 80–90% following oral administration
Benefits
- Creates a powerful psychological deterrent against alcohol consumption
- Supports long-term sobriety when combined with behavioral therapy
- Reduces alcohol craving through conditioned aversion response
- Provides a tangible tool for relapse prevention
- Enhances patient accountability in treatment programs
- Facilitates rebuilding of personal and professional relationships affected by alcoholism
Common use
Anabuse is indicated as an adjunctive therapy in the management of chronic alcohol dependence in motivated patients who wish to maintain a state of enforced sobriety. It is typically prescribed after completion of alcohol detoxification and when the patient has been alcohol-free for at least 12 hours. The medication is most effective when incorporated into a comprehensive treatment program that includes psychological support, counseling, and regular medical supervision. Patients must fully understand the consequences of alcohol consumption while taking Anabuse and must provide informed consent before initiation of therapy.
Dosage and direction
The initial dosage is typically 500 mg daily for one to two weeks, administered as a single dose in the morning. Maintenance dosage ranges from 125 mg to 500 mg daily, adjusted based on patient response and tolerance. Tablets should be swallowed whole with water, preferably at the same time each day. Administration may be supervised in clinical settings during the initial treatment phase to ensure compliance. Dosage adjustments should only be made under medical supervision, and treatment duration is individualized based on therapeutic response and patient needs.
Precautions
Patients must be thoroughly educated about the disulfiram-ethanol reaction before initiating therapy. Alcohol-containing products must be avoided, including medications, foods, toiletries, and household products that may contain ethanol. Regular liver function tests are mandatory during treatment due to potential hepatotoxicity. Patients should carry identification indicating they are taking disulfiram. Caution is advised when operating machinery or driving until response to treatment is established. Pregnancy testing should be performed in women of childbearing potential before initiation.
Contraindications
Anabuse is contraindicated in patients with severe myocardial disease, coronary artery disease, psychosis, or hypersensitivity to disulfiram or other thiuram derivatives. It must not be administered to patients who have recently ingested alcohol, metronidazole, paraldehyde, or alcohol-containing preparations. Additional contraindications include pregnancy, lactation, and severe hepatic impairment. Patients with diabetes mellitus, hypothyroidism, epilepsy, or renal impairment require careful risk-benefit assessment before prescription.
Possible side effects
Common side effects (≥1%) include drowsiness, fatigue, headache, metallic or garlic-like aftertaste, and skin eruptions. Less frequent adverse reactions (0.1–1%) may include hepatotoxicity, peripheral neuropathy, optic neuritis, and psychiatric symptoms including depression and psychosis. The disulfiram-ethanol reaction presents with flushing, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitations, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may include respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.
Drug interaction
Anabuse interacts with numerous medications including warfarin (increased anticoagulant effect), phenytoin (elevated serum levels), benzodiazepines (altered metabolism), theophylline (decreased clearance), and tricyclic antidepressants. It potentiates effects of central nervous system depressants. Concurrent use with alcohol-containing preparations must be avoided. Disulfiram inhibits several cytochrome P450 enzymes, particularly CYP2E1, requiring dosage adjustments for affected medications. A minimum 14-day washout period is recommended after disulfiram discontinuation before administering contra-indicated drugs.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Doubling the dose to make up for a missed dose is not recommended. Patients should contact their healthcare provider for guidance if multiple doses are missed. Consistent daily administration is crucial for maintaining the aversive conditioning effect. Treatment efficacy may be compromised with irregular dosing, requiring re-education about the risks of alcohol consumption.
Overdose
Symptoms of overdose include nausea, vomiting, diarrhea, neurological symptoms such as dystonia, chorea, and seizures, and cardiovascular instability. Management involves immediate gastric lavage if ingestion was recent, supportive care, and symptomatic treatment. There is no specific antidote for disulfiram overdose. Hemodialysis is not effective due to high protein binding. Patients require hospitalization for monitoring of vital signs, electrolyte balance, and hepatic function. Psychiatric evaluation may be necessary following stabilization.
Storage
Store at controlled room temperature (20–25°C or 68–77°F) in the original container with the lid tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication through take-back programs is recommended to prevent accidental ingestion or environmental contamination.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Anabuse is a prescription medication that must be used under direct medical supervision. Patients should not initiate or discontinue treatment without consulting their healthcare provider. The described disulfiram-ethanol reaction can be severe and potentially fatal. Individual results may vary, and proper medical monitoring is essential throughout treatment.
Reviews
Clinical studies demonstrate that 50–60% of motivated patients achieve sustained sobriety when Anabuse is combined with comprehensive addiction treatment. Patient testimonials frequently describe the medication as a “psychological safety net” that provides crucial support during early recovery. Medical professionals emphasize that success correlates strongly with patient motivation and adherence to concomitant therapy. Some patients report the aversive conditioning effect diminishes over time, highlighting the importance of ongoing medical supervision and dosage adjustment.